Brought to you by 
Astellas licenses Theravance gram-positive antibiotic; deal terminated
25 Jul 2014
Executive Summary
To continue building its pipeline of infectious disease therapeutics, Astellas Pharma (created from the merger of Yamanouchi and Fujisawa earlier this year) has licensed worldwide rights (excluding Japan) to develop and commercialize Theravance's telavancin lipoglycopeptide injectable antibiotic for gram-positive infections such as drug-resistant Staphylococcus aureus strains.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Astellas licenses Theravance gram-positive antibiotic; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice